Fulcrum therapeutics announces u.s. food and drug administration grants fast track designation to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (fshd)

Cambridge, mass., may 12, 2021 (globe newswire) -- fulcrum therapeutics, inc.  (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the u.s. food and drug administration (fda) has granted fast track designation to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (fshd).
FULC Ratings Summary
FULC Quant Ranking